Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE KEYNOTE ‐013

著录项

• 来源
  《British Journal of Haematology》 |2019年第3期|共4页
• 作者

  Ribrag Vincent; Avigan David E.; Green Damian J.; Wise‐Draper Trisha; Posada Juan G.; Vij Ravi; Zhu Ying; Farooqui Mohammed Z. H.; Marinello Patricia; Siegel David S.;

  展开▼
• 作者单位

  Institut Gustave RoussyVillejuif France;

  Beth Israel Deaconess Medical CenterHarvard Medical SchoolBoston MA;

  University of WashingtonSeattle WA;

  University of Cincinnati Cancer InstituteCincinnati OH;

  Central Texas Veterans Affairs Health Care SystemTemple TX;

  Center for Advanced MedicineWashington University School of MedicineSt. Louis MO;

  Merck &

  Co. Inc.Kenilworth NJ;

  Merck &

  Co. Inc.Kenilworth NJ;

  Merck &

  Co. Inc.Kenilworth NJ;

  Hackensack University Medical CenterHackensack NJ;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词

  multiple myeloma; pembrolizumab; PD ‐1 ( PDCD 1);

  机译：多发性骨髓瘤;PEMBROLIZUAB;PD -1（PDCD 1）;